

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
10 October 2002 (10.10.2002)


PCT

(10) International Publication Number  
WO 02/078616 A2

- (51) International Patent Classification<sup>7</sup>: A61K (74) Agent: CAGLAR, Oral; Sheppard Mullin Richter & Hampton LLP, 48th floor, 333 South Hope Street, Los Angeles, CA 90071 (US).
- (21) International Application Number: PCT/US02/10368
- (22) International Filing Date: 1 April 2002 (01.04.2002) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/280,593 30 March 2001 (30.03.2001) US  
60/343,473 20 December 2001 (20.12.2001) US
- (71) Applicant: INTERHEALTH NUTRACEUTICALS, INC. [US/US]; 5451 Industrial Way, Benicia, CA 94510 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): OHIA, Sunny, E. [US/US]; 5451 Industrial Way, Benicia, CA 94510 (US). PREUSS, Harry, G. [US/US]; 5451 Industrial Way, Benicia, CA 94510 (US). BAGCHI, Debasis [IN/US]; 5451 Industrial Way, Benicia, CA 94510 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: METHOD FOR INCREASING SEROTONIN LEVELS IN A PERSON BY ADMINISTRATION OF A COMPOSITION INCORPORATING (-)-HYDROXYCITRIC ACID, AND RELATED COMPOSITIONS THEREOF



(57) Abstract: A method for increasing serotonin levels in a person includes identifying a person having a deficient serotonin level and administering to the person a composition incorporating hydroxycitric acid, preferably in the form of an extract of *Garcinia cambogia*, in an amount sufficient to increase the person's serotonin levels. The method also can incorporate administering chromium, preferably in the form of oxygen-coordinated, niacin-bound chromium, and gymnemic acid, preferably in the form of an extract of *Gymnema sylvestre*, to synergistically work to further increase serotonin levels in the person.

BEST AVAILABLE COPY



*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

METHOD FOR INCREASING SEROTONIN LEVELS IN A PERSON  
BY ADMINISTRATION OF A COMPOSITION INCORPORATING (-)-  
HYDROXYCITRIC ACID, AND RELATED COMPOSITIONS THEREOF

BACKGROUND OF THE INVENTION

5                   This application claims priority from U.S. Provisional Application  
Serial Numbers 60,280,593, filed March 30, 2001, and 60/343,473, filed December  
20, 2001. The present invention relates generally to a method for increasing  
serotonin levels in a person. The present invention also relates to compositions  
that, when administered to a person, increase serotonin levels in the person.

10                   Serotonin (or 5-hydroxytryptamine, 5HT) is a neurotransmitter  
believed to be involved a wide range of mental and physical functions in the body,  
including sleep, mood, and eating behavior. Serotonin deficiency has been  
implicated in a variety of conditions, including depression, low energy, anxiety,  
affective disorder, obsessive-compulsive behavior, overeating, insomnia,  
15                   schizophrenia, migraine headaches and bulimia. It is well established that serotonin  
and peptides such as neuropeptide Y are involved in the regulation of eating  
behavior. Increased brain levels of serotonin have been linked with appetite  
suppression in preclinical experiments in animals and in clinical studies with  
human patients. These conditions can be resolved or improved dramatically when  
20                   serotonin levels of the affected person are increased.

                  Methods for increasing serotonin levels in persons suffering from  
serotonin deficiency have included use of serotonin selective re-uptake inhibitors,  
(*e.g.*, fluoxetine), compounds promoting production of serotonin, (*e.g.*, St. John's  
Wort), or compounds inhibiting the degradation of serotonin. (*e.g.*, monoamine  
25                   oxidase inhibitor antidepressants). These products, while somewhat effective, do

not provide ideal results in all cases, and they also may result in negative side effects in persons ingesting them.

It is apparent from the above that a need exists for improved methods and compositions for increasing serotonin levels in persons in a safe and convenient manner. The present invention fulfills this need and provides further related advantages.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graphical representation of the effect of exposure to (-)-hydroxycitric acid (HCA) on the release of radiolabeled serotonin from isolated, superfused, rat brain cortex slices. Stimuli were applied as follows: potassium chloride ( $K^+$ , 50 mM) standard response at fractions 5 and 6 ( $S_1$ ) and HCA at fractions 13 and 14 ( $S_2$ ). Fractions of the superfusate were collected at 6-minute intervals and analyzed for radioactivity as described herein.

Figure 2 is a graphical representation of the effect of exposure to (-)-hydroxycitric acid (HCA) on radiolabeled serotonin release from isolated, superfused rat brain cortex: control ( $K^+$ ) and in the presence of HCA (10  $\mu M$  - 1 mM). Vertical bars represent means  $\pm$  S.E.M. The number of observations is in parenthesis.

Figure 3 is a graphical representation of the increase in serum serotonin level, increase in loss of body weight, and increase in unconsumed food observed in persons treated using methods of the present invention: control (placebo), (-)-hydroxycitric acid (HCA), and HCA plus chromium and gymnemic acid (HCA+).

## SUMMARY OF THE INVENTION

The present invention resides in a method for increasing serotonin levels in a person, comprising identifying a person having or at risk for having a deficient serum serotonin levels, and administering to the person a composition  
5 incorporating an amount of (-)-hydroxycitric acid effective to increase the serotonin levels of the person.

Preferably, the amount of (-)-hydroxycitric acid administered is effective in increasing the serotonin levels in the person sufficient to suppress the appetite of or alleviate mood disorders in the person. Particular mood disorders  
10 preferably alleviated include depression, anxiety, affective disorders, premenstrual dysphoria, insomnia, sleep-wake disturbances, binge eating, bulimia and obsessive-compulsive disorders. The amount of (-)-hydroxycitric acid administered also may preferably be effective to increase serotonin levels in the person sufficient to increase energy expenditure by the person, or to promote decrease of the person's  
15 body weight.

The method preferably incorporates administration of an extract of *Garcinia cambogia* as a source of the (-)-hydroxycitric acid. The amount administered preferably is between about 2,700 and about 2,800 mg of (-)-hydroxycitric acid per day, in three approximately equal increments, preferably  
20 between about 45 and 60 minutes prior to consumption of a meal. Preferred methods also incorporate administering an amount of chromium sufficient, in combination with the (-)-hydroxycitric acid, to increase serum serotonin level in the person, in a preferred daily dose of 400 mcg. This chromium preferably is in the form of an niacin-bound, and more preferably oxygen-coordinated, niacin-bound,  
25 chromium. Preferred methods also incorporate administering an amount gymnemic acid sufficient, in combination with the (-)-hydroxycitric acid, to increase serum

serotonin level, in a preferred daily dose of 100 mg. The preferred source of gymnemic acid is an extract of *Gymnema sylvestre*.

5 The present invention also resides in a composition incorporating hydroxycitric acid, niacin-bound chromium, and gymnemic acid, in the preferred individual dosages discussed above (*i.e.*, between about 900 and 930 mg (-)-hydroxycitric acid, about 133 mcg chromium, and about 33 mg gymnemic acid). Preferred compositions consist essentially of an extract of *Garcinia cambogia*, an extract of *Gymnema sylvestre*, and niacin-bound chromium, preferably in amounts to provide the amounts of hydroxycitric acid, niacin-bound chromium, and  
10 gymnemic acid discussed above (*i.e.*, between about 1,500 and 1,550 mg of *Garcinia cambogia*, about 1.3 mg of niacin-bound chromium, and about 130 mg of extract of *Gymnema sylvestre*). The composition may be in the form of a pill, tablet, capsule, powder, lozenge, or gum, or liquid. The composition also may be in the form of a food or beverage, such as a food bar or shake.

15 Other features and advantages of the present invention should become apparent from the following detailed description of the invention, taken with the accompanying drawings, which illustrate the principles of the invention.

#### DETAILED DESCRIPTION OF THE PREFERRED METHOD

20 The present invention resides in a method for increasing serotonin levels in persons and alleviating various conditions linked to serotonin deficiency in those persons. The method includes identifying a person who is or is at risk for having deficient serotonin levels and administering to the person a composition comprising a salt of (-)hydroxycitric acid (HCA) in an amount effective to alleviate the deficiency. The present invention also resides in a composition comprising  
25 HCA, chromium, and gymnemic acid, preferably as a composition consisting essentially of preferred sources of HCA, chromium, and gymnemic acid.

Ingestion of a salt of (-)hydroxycitric acid is known to suppress appetite, inhibit fat production and decreases body weight in animals and persons. HCA has been shown to reduce food intake in experimental animals, suggesting a role for this agent in the treatment of obesity. HCA is a competitive inhibitor of ATP-citrate lyase, an extra-mitochondrial enzyme involved in the initial steps of *de novo* lipogenesis. Consequently, HCA reduces the transformation of citrate into acetyl coenzyme A, a step necessary for the formation of fatty acids in the liver. In the presence of HCA, there is increased production of hepatic glucogen, which has been believed to activate glucoreceptors leading to a sensation of fullness and reduced appetite. This mechanism of appetite suppression, however, has never been proven. It also has been shown that HCA-induced increases in energy expenditure may account, at least in part, for the observed inhibitory effect of this anorectic agent on body weight gain in rats.

Despite the known properties of HCA and its action at the metabolic level, no study has investigated its possible effect on neurotransmitters associated with the control of appetite and eating behavior. Recently, it has been found that consumption of HCA by persons increases their serum serotonin levels, reduces their appetites, and decreases their food intake. This increase in serotonin levels also may prove beneficial in addressing the other conditions known to be affected by low serotonin levels, including depression, low energy, anxiety disorder, obsessive-compulsive behavior, insomnia, schizophrenia, migraine headaches, and bulimia.

A preferred known composition incorporating HCA for use in the methods of the present invention is an extract of the *Garcinia cambogia* fruit containing approximately 60% calcium/potassium salt of (-)hydroxycitric acid, marketed under the name Super CitriMax™ by InterHealth Nutraceuticals of Benicia, California. This extract is highly soluble in water, and it is readily

absorbed and retained by persons. Studies have shown that blood levels of the extract increase for at least 2 hours and remained in the blood for more than 4 to 9 hours after ingestion. Studies also show that eating a full meal shortly after consuming the extract reduced its absorption by about 60%. Thus, it is  
5 recommended that compositions containing the extract be taken at least 30 to 60 minutes before meals to provide maximum efficacy.

Preferred aspects of the method of the present invention incorporate administering compositions comprising chromium, gymnemic acid, or both of these. It has been surprisingly determined that consumption by persons of HCA in  
10 combination with these compounds provides for even greater increases in serotonin levels than consumption of HCA alone.

Chromium incorporated into the compositions used in the method of the present invention preferably is in an oxygen-coordinated, niacin-bound form. This form of chromium is known to be more bioavailable and biologically active  
15 that other known forms. A preferred source of this chromium is described in U.S. Patent Nos. 4,934,855, 4,954,492, and 5,194,615 and is supplied by InterHealth Nutraceuticals, marketed under the name ChromeMate®. ChromeMate® has been shown to promote weight loss and loss of body fat in persons ingesting it, with no adverse effects observed from this ingestion. No prior studies on chromium,  
20 however, have determined or suggested increases in serotonin levels from ingestion of chromium, either alone or in combination with other compounds.

Gymnemic acid has been shown to increase the production of insulin by stimulating the production of new insulin-promoting "beta-cells" cells in the pancreas. Gymnemic acid also facilitates insulin release from the beta-cells into the  
25 blood stream by increasing beta-cell membrane permeability, and inhibits the absorption of sugar molecules in the intestines during digestion, thus reducing increases in blood sugar levels. A preferred source of gymnemic acid in



compositions used with the method of the present invention is *Gymnema sylvestre* extract supplied by InterHealth Nutraceuticals of Benicia, California. *Gymnema sylvestre* is a traditional Ayurvedic herb that is known to play a role in weight control by helping to promote normal blood sugar levels and reduce sugar  
5 cravings. *Gymnema sylvestre* also has also been shown to lower cholesterol in animal models. Despite its known properties, gymnemic acid or the *Gymnema sylvestre* previously have not been determined to affect serotonin levels in persons ingesting them.

Particularly referred methods of the present invention include  
10 administration of a composition incorporating between approximately 2,700 and 2,800 mg of HCA daily. Preferred administration of the composition is orally, in three daily doses roughly 30 to 60 minutes before meals. Additional preferred methods include administration of a composition further incorporating  
approximately 100 mg of gymnemic acid, or approximately 400 mcg of chromium,  
15 or both of these. As discussed above, the preferred source of gymnemic acid is *Gymnema sylvestre* extract. Approximately 400 mg of *Gymnema sylvestre* extract serves as a source of 100 mg of gymnemic acid. The preferred source of chromium is ChromeMate™, the oxygen-coordinated, niacin-bound chromium previously  
discussed. Approximately 4 mg of ChromeMate™ serves as a source of 400 mcg  
20 of chromium.

Methods of the present invention also include administration of  
compositions incorporating inert ingredients or diluents, such as sugar or other inert  
ingredients commonly used in food products. The composition administered may  
be in various forms commonly used for dietary supplements, including pill, tablet,  
25 capsule, powder, lozenge, gum, or liquid. The step of administering can include administering the compositions as part of functional foods and beverages, including  
bars, shakes, drinks, and other processed or prepared foods or beverages.

## EXAMPLES

Both preclinical and clinical studies were conducted to determine the efficacy of the methods and compositions of the present invention. The studies and their results are discussed in turn below.

# 1. Preclinical study of serotonin increase from HCA

A study was conducted to evaluate the effect of HCA on brain serotonin levels. The aim of the study was to examine the effect of HCA on the release of radiolabeled serotonin from rat brain cortex slices *in vitro*.

## 5 a. Methods

Methods previously known for studies of radiolabeled serotonin release were employed. Isolated rat brain cortex slices were incubated in oxygenated Krebs buffer solution containing 800 nM radiolabeled serotonin, the monoamine oxidase inhibitor pargyline (10  $\mu$ M), and the cyclooxygenase inhibitor flurbiprofen (3  $\mu$ M) at 37°C. A natural extract of 60% (-)-hydroxycitric acid (HCA) from *Garcinia cambogia* (commercially known as Super CitriMax™, from InterHealth Nutraceuticals) was used. Radiolabeled serotonin was purchased from NEN Life Sciences, Boston, MA. The Krebs solution used had the following composition (millimolar): potassium chloride, 4.8; sodium chloride 118; calcium chloride, 1.3; potassium dihydrogen phosphate, 1.2; sodium bicarbonate, 25; magnesium sulfate, 2.0; and dextrose, 10 (pH 7.4).

After incubation, tissues were rinsed, mounted between nylon mesh-cloth and placed in thermostatically-controlled superfusion chambers. Tissues were superfused at a rate of 0.5ml/min with oxygenated Krebs solution containing clomipramine (10  $\mu$ M), a serotonin reuptake inhibitor. Fractions of the superfusate were collected at 6-minute intervals, and 3-ml aliquots of each fraction was combined with 12 ml of aqueous scintillation cocktail marketed under the name Ecolume, by ICN Radiochemicals of California) and analyzed for radioactivity by liquid scintillation spectrometry.

After an initial 2 hours of superfusion to establish a stable baseline of spontaneous tritium efflux, release of radiolabeled serotonin was elicited by consecutive potassium-depolarizing ( $K^+$ , 50 mM) stimuli applied at 144 minutes ( $S_1$ ) and at 198 minutes ( $S_2$ ) after the onset of superfusion. In some experiments, tissues were exposed to different concentrations of HCA for 12 minutes before the second  $K^+$  stimuli at  $S_2$ . When HCA was tested on its own, the  $K^+$  (50 mM;  $S_1$ ) peak was used as the standard (or control) response. In this case, effects induced by HCA on radiolabeled serotonin release were then compared with the standard  $K^+$  response. Both  $K^+$  and HCA-induced radiolabeled serotonin release were estimated by subtraction of the extrapolated basal tritium efflux from total tritium release in the 20-minute period after the onset of stimulation. Basal (unstimulated) tritium efflux was assumed to decline linearly between pre-stimulation and post-stimulation fractions. Stimulation-evoked radiolabeled serotonin release during  $S_1$  and  $S_2$  was determined graphically, and the ratio of the two peaks ( $S_1/S_2$ ) was calculated and compared with untreated control preparations.

Results obtained were expressed as absolute  $S_1/S_2$  ratios. Data from different experiments (control and test) were pooled and then subjected to statistical analysis. Except where indicated otherwise, values given are arithmetic means  $\pm$  SEM. Significance of difference between control and test values was evaluated using analysis of variance (ANOVA) followed by Dunnett's test. Differences with P values  $< 0.05$  were accepted as statistically significant.

## b. Results

Results of the experiment are illustrated in Figures 1 and 2. Application of an iso-osmotic concentration of  $K^+$  (50 mM) elicited a peak of overflow of radiolabeled serotonin release, an effect that can be repeated more than twice in the same slice of brain cortex. The ratio of the size of the first ( $S_1$ ) and second ( $S_2$ ) peaks of stimulation was  $0.91 \pm 0.07$  ( $n = 7$ ) indicating that there was

no significant depletion of neurotransmitter occurring between stimuli. In preliminary experiments, the effect of different concentrations of HCA (10  $\mu$ M - 1 mM) applied 12 minutes before the second K<sup>+</sup> stimuli (S<sub>2</sub>) were examined. At these concentrations, HCA had no significant effect on the second K<sup>+</sup> response even though it changed the baseline of spontaneous radiolabeled serotonin efflux. Consequently, the direct effect of HCA on basal radiolabeled serotonin release from brain cortex slices were investigated. For these experiments, the K<sup>+</sup> stimulus was applied at S<sub>1</sub>, and then the effect of HCA on basal tritium efflux was tested at fraction number 12. As represented by the illustration in Figure 1, HCA (300  $\mu$ M) elicited an increase in the release of radiolabeled serotonin over baseline values. Next, the effect of different concentrations of HCA (10  $\mu$ M - 1 mM) on basal release of radiolabeled serotonin from cortical slices was examined. HCA caused a concentration-related increase in basal efflux of radiolabeled serotonin, reaching a maximum at 300  $\mu$ M (Figure 2). The overflow of radiolabeled serotonin induced by the maximal concentration of HCA (300  $\mu$ M) was equivalent to the release induced by the standard concentration of K<sup>+</sup> (50 mM).

### c. Discussion

The results of this study determined that HCA alters the release and/or availability of serotonin in the brain slices, specifically by increasing the release of serotonin from neuronal stores in the brain cortex in a concentration-dependent fashion. Exposure of the rat brain cortex slices to different concentrations of HCA had no significant effect on K<sup>+</sup>-depolarization evoked release of radiolabeled serotonin. However, on its own, HCA increased the basal release of tritium-labeled 5-HT in a concentration-dependent fashion. The maximal effect caused by HCA on radiolabeled serotonin release was equivalent to responses elicited by the K<sup>+</sup> depolarizing stimuli. The exact mechanism whereby HCA induces an increase in basal release of radiolabeled serotonin from rat brain cortex slices is unknown. HCA may act via a "reserpine-like" or "tyramine-like"

action to increase the efflux of radiolabeled pools of 5-HT in the brain cortex. A reserpine-like action may involve HCA induced interference with the storage of radiolabeled serotonin in vesicles whereas, a tyramine-like effect could involve vesicular release of radiolabeled serotonin in a non-exocytotoxic manner. It is also  
5 feasible that HCA may act to prevent the reuptake of released radiolabeled serotonin, resulting in an increased efflux of this amine into the superfusate.

## 2. Clinical Study

The effects of administering compositions within the scope of the present invention were tested. A double-blind, placebo-controlled human clinical  
10 trial was conducted using a composition incorporating: the HCA extract described above, or the HCA extract in combination with an oxygen-coordinated niacin-bound chromium (ChromeMate®, supplied by InterHealth), and a standardized *Gymnema sylvestre* extract (also supplied by InterHealth).

### a. Methods

15 Approximately 80 moderately obese human subjects were enrolled in the study. All subjects were placed on a daily diet of 2,000 kcal, weighing 2,250 grams. All food was prepared and delivered to the subjects, and all food intake was strictly supervised by trained dieticians. All subjects also underwent a 30 minute walking exercise program, five times a week, which was supervised by a trained  
20 exercise specialist.

The subjects were randomly divided into three groups. The first group was given a placebo. The second group was given a daily dose of 4,667 mg of *garcinia cambogia* extract (providing 2,800 mg HCA per day). The third group was given a daily dose of 4,667 mg of a combination of *garcinia cambogia* (2,800  
25 mg HCA), 4 mg of niacin-bound chromium (providing 400 mcg of elemental

chromium), and 400 mg of *Gymnema sylvestre* extract (providing 100 mg gymnemic acid). The subjects received their respective compositions in three equally-divided doses 30 to 60 minutes before breakfast, lunch and dinner for eight weeks. These dosage levels of HCA were determined by extrapolation of successful earlier animal trials, as well as review of optimal micromolar concentrations of HCA in *ex vivo* brain tissue resulting in maximum serotonin release.

The persons were assessed for changes in serum serotonin levels, body weight, and food intake. As discussed above, increases in serum serotonin levels relate to reduced appetite. Food intake was measured by monitoring the amount of food left unconsumed after each meal by the subjects. The amount of food left unconsumed while taking either the placebo or either of the HCA compositions was compared to the amount of food left unconsumed before the subjects began taking the compositions (*i.e.*, the baseline). Changes in each of these factors were measured in the persons and averaged to produce the figures in Table 1.

#### b. Results

Results of the testing are shown in Table 1 below and Figure 3.

Table 1: Results of Administration of Compositions

<u>Tested Factor</u>	<u>Placebo</u>	<u>HCA</u>	<u>HCA + chromium + gymnemic acid</u>
<u>Body weight</u>			
Pounds lost	3.5	10.0	12.8
% decrease	1.9	5.0	6.5
<u>Serum serotonin level</u>			
mg/dl increase	20.1	119.1	149.3
% increase	10.9	48.5	70.4

<u>Tested Factor</u>	<u>Placebo</u>	<u>HCA</u>	<u>HCA + chromium + gymnemic acid</u>
<u>Food left unconsumed</u> grams % increase from baseline	71.9 (3.6)	249 206	328 370

5                    In addition to the results noted above, no adverse effects were observed in the patients ingesting the compositions of the study.

c.        Discussion

10                    The data from this Example indicate that administration of the specified levels of HCA extract results in increases in serotonin levels and in related effects on body weight and food consumption. Specifically, serum serotonin levels, as shown in Figure 3, increased almost 50 percent in subjects consuming HCA alone, compared to an increase of 10 percent in those consuming a placebo. Serotonin levels rose more dramatically, approximately 70 percent, in subjects consuming HCA in combination with chromium and gymnemic acid.

15                    Additionally, this increase in serotonin level led to increased losses of body weight and decreased food intake. Body weight losses increased two- to three-fold in subjects consuming the active compositions, compared to those consuming the placebo.

20                    The results of the two studies indicate that consumption of HCA by persons can lead to increased serotonin levels in those persons, resulting in alleviation of conditions relating to low serotonin levels. Consumption of HCA can also be incorporated into a method of increasing serotonin levels in persons to alleviate any other conditions caused by serotonin deficiency. For example, as discussed above, current therapies for depression, insomnia, and migraine

25                    headaches involve increasing the serotonin levels in the affected persons.



Consumption of a sufficient amount of HCA by a person suffering from depression, insomnia, or migraine headaches could raise serotonin levels and therefore eliminate these symptoms. Additionally, combining consumption of HCA with oxygen-coordinated niacin-bound chromium (incorporating elemental chromium), and *Gymnema sylvestre* extract (incorporating gymnemic acid), provides for increased efficacy of the method, increasing serum serotonin levels greater than consumption of HCA alone, further improving alleviation of the negative conditions discussed above. Administration of the three compounds works synergistically to substantially increase serotonin levels in persons consuming the compounds.

10                    Although the invention has been disclosed in detail with reference only to the preferred embodiments, those skilled in the art will appreciate that additional methods and compositions can be made without departing from the scope of the invention.

We claim:

1. A method for increasing serotonin levels in a person,  
comprising:  
identifying a person having or at risk for having deficient serotonin  
levels; and  
5 administering to the person a composition comprising an amount of  
(-)-hydroxycitric acid effective to increase serotonin levels in the person.
2. A method as defined in claim 1, wherein the step of  
administering comprises administering an amount of (-)-hydroxycitric acid effective  
to increase serotonin levels in the person sufficient to suppress the appetite of the  
person.
3. A method as defined in claim 1, wherein the step of  
administering comprises administering an amount of (-)-hydroxycitric acid  
effective to increase serotonin levels sufficient to alleviate mood disorders in the  
person.
4. A method as defined in claim 3, wherein the mood disorders  
include depression, anxiety, affective disorders, premenstrual dysphoria, insomnia,  
sleep-wake disturbances, binge eating, bulimia, and obsessive-compulsive  
disorders.
5. A method as defined in claim 1, wherein the step of  
administering comprises administering an amount of (-)-hydroxycitric acid effective  
to increase serotonin levels in the person sufficient to increase energy expenditure  
by the person.

6. A method as defined in claim 1, wherein the step of administering comprises administering an amount of (-)-hydroxycitric acid effective to increase serotonin levels in the person sufficient to promote decrease of body weight of the person.

7. A method as defined in claim 1, wherein the step of administering comprises administering a composition comprising an extract of *Garcinia cambogia*.

8. A method as defined in claim 1, wherein the step of administering comprises administering between about 2,700 and about 2,800 mg of (-)-hydroxycitric acid per day.

9. A method as defined in claim 1, wherein the step of administering comprises administering the composition in three approximately equal increments per day.

10. A method as defined in claim 1, wherein the step of administering comprises administering the composition between about 45 and about 60 minutes prior to consumption of a meal by the person.

11. A method as defined in claim 1, wherein the step of administering comprises administering a composition comprising an amount of chromium sufficient, in combination with the amount of (-)-hydroxycitric acid, to increase serotonin levels in the person.

12. A method as defined in claim 11, wherein the step of administering comprises administering a composition comprising niacin-bound chromium.

13. A method as defined in claim 12, wherein the step of administering comprises administering a composition comprising oxygen-coordinated, niacin-bound chromium.

14. A method as defined in claim 11, wherein the step of administering comprises administering about 400 mcg of chromium per day.

15. The method of claim 1, wherein the step of administering comprises administering a composition comprising an amount of gymnemic acid sufficient, in combination with the amount of (-)-hydroxycitric acid, to increase serotonin levels in the person.

16. A method as defined in claim 15, wherein the step of administering comprises administering a composition comprising an extract of *Gymnema sylvestre*.

17. A method as defined in claim 15, wherein the step of administering comprises administering about 100 mg of gymnemic acid per day.

18. A composition comprising (-)-hydroxycitric acid, chromium, and gymnemic acid.

19. A composition as defined in claim 18, comprising between about 900 and about 930 mg (-)-hydroxycitric acid, about 133 mcg chromium, and about 33 mg gymnemic acid.

20. A composition as defined in claim 18, wherein the composition consists essentially of an extract of *Garcinia cambogia*, an extract of *Gymnema sylvestre*, and niacin-bound chromium.

21. A composition as defined in claim 20, wherein the composition consists essentially of between about 1,500 and about 1,550 mg of the extract of *Garcinia cambogia*, about 130 mg of the extract of *Gymnema sylvestre*, and about 1.3 mg of the niacin-bound chromium.

22. A composition as defined in claim 18, wherein the composition is in the form of a pill, tablet, capsule, powder, lozenge, or gum, or liquid.

23. A composition as defined in claim 18, wherein the composition is in the form of a food or beverage.

24. A composition as defined in claim 23, wherein the food is in the form of a food bar.

25. A composition as defined in claim 23, wherein the beverage is in the form of a shake.




FIGURE 1




FIGURE 2

3/3




FIGURE 3



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**